A preview of an article about a clinical trial testing a PD‑L1 antibody as an anti‑inflammatory approach for early Alzheimer's disease, inviting readers curious about novel therapeutic strategies.
Key Takeaways
- Aging in general is characterized by an increased level of constant inflammatory signaling
- Reduced flow allows metabolic waste to build up in brain tissue
- Comprehensively dealing with the inflammation of old age is a task that will require more than one therapy